S-1: Enveric Biosciences Seeks Capital Through Share and Warrant Offering

Enveric Biosciences is offering shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants, to raise capital for product development and general corporate purposes.

Summary

• Enveric Biosciences is conducting a public offering to sell shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants.
• The offering aims to raise capital for the pre-clinical development of EB-003, working capital, and general corporate purposes.
• The offering includes up to [] shares of common stock and accompanying warrants, or up to [] pre-funded warrants and accompanying warrants.
• The combined public offering price per share of common stock and accompanying warrant is assumed to be $ [], which is equal to the last reported sale price of the common stock on the Nasdaq Capital Market on [], 2025.
• The combined public offering price per pre-funded warrant and accompanying warrant is assumed to be $ [], which is equal to the last reported sale price of the common stock on the Nasdaq Capital Market on [], 2025, minus $0.0001.
• The warrants will have an exercise price of $[] per share and will be exercisable beginning on the effective date of stockholder approval, or immediately if certain pricing conditions are met.
• The warrants will expire five years from the initial exercise date.
• Pre-funded warrants are offered to purchasers who would own more than 4.99% (or 9.99%) of the outstanding common stock after the offering, and are exercisable at $0.0001 per share.
• The offering will terminate on [], 2025, unless terminated earlier by the company.
• The company has engaged [] as the exclusive placement agent for the offering and will pay a cash fee equal to 7.0% of the gross proceeds, a management fee equal to 1.0% of the gross proceeds, and will reimburse the placement agent for certain expenses.
• The company will also issue placement agent warrants to purchase a number of shares of common stock equal to 7.0% of the aggregate number of shares of common stock and pre-funded warrants being offered at an exercise price equal to 125% of the combined public offering price per share of common stock and accompanying warrant.

Sentiment

Score: 3

Explanation: The document highlights significant risks and uncertainties, including the company's going concern status, lack of revenue, and dependence on future capital raises. While there are some positive aspects, such as the potential for product development, the overall tone is cautious and indicates a high level of investment risk.

Positives

• The offering will provide capital for the pre-clinical development of EB-003, working capital, and general corporate purposes.
• The company has the flexibility to terminate the offering at any time.
• The company has engaged a placement agent to assist with the offering.

Negatives

• There is no minimum amount of securities or proceeds required to close the offering, which may result in the company not raising sufficient capital.
• The company has broad discretion in how it uses the proceeds of the offering.
• The offering price may be at a discount to the current market price of the common stock.
• There is no established public trading market for the warrants or pre-funded warrants, and the company does not expect one to develop.
• The warrants will not be exercisable until stockholder approval is obtained, unless certain pricing conditions are met.
• The company may be required to repurchase the warrants, which may prevent or deter a third party from acquiring the company.

Risks

• The company will require substantial additional funding, which may not be available on acceptable terms.
• The company may not use the proceeds of the offering effectively.
• The company's common stock has often been thinly traded, so investors may be unable to sell at or near ask prices.
• If the company is required to obtain Warrant Stockholder Approval, until such approval is obtained the warrants will not be exercisable, and if such approval is not obtained the warrants will have no value.
• The company does not intend to pay dividends in the foreseeable future.
• Purchasers in this offering may experience immediate and substantial dilution in net tangible book value.
• There is no public market for the warrants or pre-funded warrants being offered in this offering.
• The warrants are speculative in nature.
• This is a best efforts offering, and no minimum amount of securities is required to be sold.
• FINRA sales practice requirements may limit a stockholders ability to buy and sell the company's securities.
• The company's independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on the success of its prospective product candidates, which are in early stages of development.
• The company may encounter difficulties that may delay, suspend or scale back its efforts to advance additional early research programs.
• Catastrophic events could have a material adverse effect on the company's business.
• The company has significant and increasing liquidity needs and may require additional funding.
• The company depends on its current key personnel.
• There has been limited study on the effects of psychedelics, and future clinical research studies may lead to conclusions that dispute or conflict with the company's understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing, and social acceptance of psychedelics.
• The company expects to face intense competition, often from companies with greater resources and experience.
• The company's current and future preclinical and clinical studies may be conducted outside the United States, and the FDA may not accept data from such studies.
• Because the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, the company may not have favorable results in its planned and future clinical trials.
• Regulatory approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
• Business interruptions could delay the company in the process of developing its product candidates.
• The company's employees may engage in misconduct or other improper activities.
• The company's proprietary information, or that of its customers, suppliers and business partners, may be lost or the company may suffer security breaches.
• Failure of the company's information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt the operation of its business.
• The company's operating results may vary significantly in future periods.
• The company has significant ongoing costs and obligations.
• The company may rely on third parties to plan and conduct preclinical and clinical trials.
• The company relies on third party contract manufacturers.
• Termination or non-renewal of key licenses and agreements could adversely affect the company.
• Negative results from clinical trials or studies of others and adverse safety events involving the company's Psychedelic Derivatives could adversely affect the company.
• Clinical trials of the company's Psychedelic Derivatives may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or not otherwise produce positive results.
• Raw materials requiring regulatory approval could cause delays or result in losses for the company.
• Possible increase in costs beyond what is currently expected as a result of regulatory review.
• The company has never been profitable, has no products approved for commercial sale, and to date has not generated any revenue.
• The company has no licensing, marketing or distribution experience.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Changes in patent law and its interpretation could diminish the value of patents in general.
• Failure to manage growth could adversely affect the company.
• Insurance and uninsured risks could adversely affect the company.
• Litigation could adversely affect the company.
• Conflicts of interest could adversely affect the company.
• The psychedelic therapy industry and market are relatively new and may not continue to exist or grow as anticipated.
• The psychedelic medicine market will face specific marketing challenges.
• The psychedelic therapy industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market data.
• The psychedelic therapy and biotechnology industries are experiencing rapid growth and increased competition.
• Changes in legislation, regulations and guidelines could adversely affect the company.
• The company's current and prospective product candidates, and the development thereof, are or will be subject to the various federal and state laws and regulations relating to the safety and efficacy of health products.
• The psychedelic-derived therapeutic candidates the company is developing or may develop in the future are subject to controlled substance laws and regulations.
• The psychedelic APIs the company intends to utilize are listed as Schedule I controlled substances under the CSA in the United States and under similar controlled-substance legislation in other countries.
• Regulatory approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
• Clinical trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination.
• Certain third-parties the company relies on to conduct its operations are subject to regulatory requirements.
• Difficulty or delays in enrolling patients in clinical trials may result in delay or prevention of necessary regulatory approvals.
• Any failure by the company to comply with existing regulations could harm its reputation and operating results.
• The company may be subject to federal, state and foreign healthcare laws and regulations.
• There is a high rate of failure for drug candidates proceeding through clinical trials.
• Serious adverse events or other safety risks could require the company to abandon development and preclude, delay or limit approval of its prospective products.
• The company may voluntarily suspend or terminate its clinical trials.
• The company may not be able to adequately protect or enforce its intellectual property rights.
• The company may not be able to adequately prevent disclosure of trade secrets and other proprietary information.
• The company may not be able to protect its intellectual property rights effectively outside of the United States.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• If the company is not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of its technology and products could be significantly diminished.
• The company may not be able to protect its intellectual property rights effectively outside of the United States.
• The company's financial condition would be adversely impacted if its intangible assets become impaired.
• In the event that the company fails to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing requirements of Nasdaq, its common stock may be delisted.
• The market price of the company's common stock may be subject to significant fluctuations and volatility.
• Certain stockholders could attempt to influence changes within the company which could adversely affect its operations.
• If securities analysts do not publish research or reports about the company's business, or if they publish negative evaluations, the price of its common stock could decline.
• Anti-takeover provisions under Delaware corporate law may make it difficult for the company's stockholders to replace or remove its board of directors.
• The company may not be able to maintain an active trading market for its common stock.
• The company maintains its cash at financial institutions, often in balances that exceed federally insured limits.
• The company may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.

Future Outlook

The company intends to use the net proceeds from this offering for product development, working capital and general corporate purposes. The company will need to raise additional capital to fund its operations and continue to support its planned development and commercialization activities.

Industry Context

The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The use of psychedelics for medicinal purposes has shown promise in various studies and the company believes that both regulators and the public have an increasing awareness and acceptance of this promising field.

Comparison to Industry Standards

• The company is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.
• Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical and early clinical development.
• The company faces competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.
• The company's product candidates will compete with existing therapies and new therapies that may become available in the future.

Related Party Transactions

• Dr. DeWitt has provided research and development services as an advisory consultant to the Company since May 2022, through DeuteRx, LLC, of which Dr. DeWitt is a President, Chief Executive Officer and Chair of its Board of Directors.
• The Company and David Johnson, the Companys former Executive Chairman, entered into a consulting agreement on January 1, 2023.

Stakeholder Impact

• The offering will dilute the ownership of existing shareholders.
• The company's ability to continue as a going concern is dependent upon its ability to obtain substantial additional funding.
• The company's success will depend on its ability to successfully develop and commercialize its prospective product candidates.
• The company's operations and business could be disrupted by natural disasters, industrial accidents, public health issues, cybersecurity incidents, and other catastrophic events.

Next Steps

• The company intends to use the net proceeds from this offering for product development, working capital and general corporate purposes.
• The company intends to advance EB-003 into formal pre-clinical studies in support of a future IND filing.
• The company intends to promptly, and in no event later than 90 days after the consummation of this offering, seek Stockholder Approval for the issuance of shares of common stock issuable upon exercise of the warrants.

Key Dates

Keywords

biotechnology, neuroplastogenic, small-molecule therapeutics, depression, anxiety, addiction disorders, Psybrary, EVM201 Series, EVM301 Series, EB-003, EB-002, psilocin, prodrugs, clinical trials, capital raise, warrants, pre-funded warrants, placement agent, Nasdaq